This document is a published patent application from the USPTO detailing a novel pharmaceutical formulation. The application, filed on August 8, 2025, and published as US20260083671A1, describes a stabilized formulation comprising a recombinant stabilized galectin-9 protein, specifically designed for improved stability through the combination of a buffer and a stabilizer.

This publication represents a new intellectual property filing related to drug formulation. While not a regulatory rule, it signals potential future developments in therapeutic products. Companies in the pharmaceutical sector should be aware of this filing as it pertains to potential new drug compositions and may impact their own research and development or patent strategies.